Matthew K. Szot, Chief Financial Officer of Cadrenal Therapeutics, separated from the company on May 28, 2026, with a severance package of $365,806 payable in installments through September 2026. The departure represents a leadership change at the biopharmaceutical company during a period of operational restructuring.